Neil Herskowitz Buys Shares of Journey Medical Corporation

Neil Herskowitz, an insider at Journey Medical Corporation, bought 10,000 shares of the company on June 25, 2026. This purchase did not fall under a pre-planned trading arrangement. Journey Medical, trading on the NasdaqCM under the ticker DERM, saw its shares trade near $6.22 on Saturday.

Insider Buying and Selling at Journey Medical Corporation

On June 25, 2026, several insiders at Journey Medical Corporation made stock purchases. Neil Herskowitz acquired 10,000 shares, alongside Justin Adam Smith and Michael Cooper Pearce, who also bought 10,000 shares each. Earlier, on April 22, CFO Joseph Benesch and COO Ramsey Alloush made significant purchases, with Benesch buying 70,767 shares and Alloush acquiring 62,795 shares.

Other Institutional Activity in Journey Medical Corporation

Among institutional investors, Wasatch Advisors LP increased its stake by 817,095 shares, ending with 2,133,370 shares valued at about $10.0 million, a 62.1% increase. Tang Capital Management LLC reduced its holdings by 244,596 shares, holding 1,610,000 shares worth approximately $7.6 million, a 13.2% decrease. Vanguard Capital Management LLC opened a new position with 1,082,080 shares valued at $5.1 million. BlackRock, Inc. added 253,078 shares, bringing its total to 972,862 shares worth $4.6 million, a 35.2% increase.

Journey Medical Corporation Stock Down 11.4%

Shares of Journey Medical Corporation traded near $6.22 on Saturday. The company has a market cap of around $182.3 million. Although it currently has no meaningful P/E ratio due to lack of profitability, its forward P/E is -110.3. The stock has a beta of 1.097, indicating slightly higher volatility compared to the market. Its 52-week range is between $4.31 and $9.55, with a 50-day moving average of $5.79 and a 200-day moving average of $7.12. The company maintains a current ratio of 1.717 and a quick ratio of 1.38, with a debt-to-equity ratio of 82.602.

Analysts Set New Price Targets

On March 26, 2026, HC Wainwright & Co. reiterated its buy rating on Journey Medical Corporation, setting a price target of $13.0. The consensus among analysts is a strong buy, with a mean target price of $13.5, based on four analyst opinions.

About Journey Medical Corporation

Journey Medical Corporation is a Scottsdale, Arizona-based pharmaceutical company focused on dermatological products. It offers a range of treatments for conditions like hyperhidrosis, acne, and rosacea, including well-known brands like Qbrexza and Accutane. Founded in 2014, the company is led by CEO Claude Maraoui and employs 58 people.

Bottom Line

Neil Herskowitz's recent purchase of Journey Medical Corporation shares highlights ongoing insider interest in the company. Investors often watch insider transactions as potential indicators of confidence or strategy shifts. However, it's important to remember that this information is backward-looking and may not reflect the current state of affairs.